05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicines for human purposes; chemico-pharmaceutical
preparations; raw material medicine; biomedicine;
pharmaceutical herbs for medical purposes; prepared Chinese
medicine; capsules for medicines; pharmaceutical
preparations; dietetic substances adapted for medical use;
bath preparations, medicated; balsamic preparations for
medical purposes; preparations for the treatment of burns;
syrups for pharmaceutical purposes; vitamin preparations;
sunburn preparations for pharmaceutical purposes; vaccines;
detergents for medical purposes; disinfectants for hygiene
purposes; digestives for pharmaceutical purposes; drugs for
medical purposes; medicine cases, portable, filled; mineral
water for medical purposes; salts for medical purposes;
purgatives; meal for pharmaceutical purposes; flour for
pharmaceutical purposes; febrifuges; medicinal tea;
nervines; anthelmintics; gelatine for medical purposes;
germicides; greases for medical purposes; chemical
preparations for the diagnosis of pregnancy; medicinal oils;
medicinal herbs; lotions for pharmaceutical purposes;
ointments for pharmaceutical purposes; pectin for
pharmaceutical purposes; herb teas for medicinal purposes;
pharmaceutical preparations for skin care; pharmaceutical
preparations for treating dandruff; first-aid boxes, filled;
medicinal roots; tonics [medicine]; sedatives; soporifics;
sugar for medical purposes; biological preparations for
medical purposes; medical preparations for slimming
purposes; by-products of the processing of cereals for
dietetic or medical purposes; chemical preparations for
pharmaceutical purposes; medicines for dental purposes;
diagnose preparations for medical purposes; medicinal
drinks; ferments for pharmaceutical purposes; chemical
preparations for medical purposes; chemical reagents for
medical or veterinary purposes; dietary fiber; enzyme
preparations for medical purposes; amino acids for
pharmaceutical purposes; mouthwashes for medical purposes;
appetite suppressants for medical purposes; adjuvants for
medical purposes; weight-reducing aid [medicine]; medicine
for the treatment of tanning skin; antioxidant medicine;
acne treatment preparation; lysine electuary; oral
rehydration salts; medicinal liquor; ginseng electuary;
ginseng for medicinal purposes; medlar for medicinal
purposes; weight-reducing tea; dietetic foods adapted for
medical purposes; dietetic beverages adapted for medical
purposes; nutritional additives for medical purposes; food
for babies; milk powder for infants; air purifying
preparations; animal washes; veterinary preparations;
medicated animal feed; biocides; vermin destroying
preparations; sanitary towels; wadding for medical purposes;
medical dressings; rubber for dental purposes; teeth filling
material; diaper for pets.
2.
ANTIDEPRESSANT AND ANXIOLYTIC SUBSTITUTED CINNAMAMIDE COMPOUND
The present application relates to an antidepressant and anxiolytic substituted cinnamamide compound, i.e., compound M2. The present application also provides a pharmaceutical composition containing compound M2 or a solvate thereof or a pharmaceutically acceptable salt thereof, and an antidepressant, anxiolytic, or antidepressant and anxiolytic application.
C07D 317/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Provided in the present application are the use of andrographolide, or a pharmaceutically acceptable salt thereof, or a solvate thereof in the preparation of a drug for treating hearing impairment, and the use of a pharmaceutical composition consisting of andrographolide or a pharmaceutically acceptable salt thereof or a solvate thereof, and other drugs for treating hearing impairment in the preparation of a drug for treating hearing impairment, wherein the hearing impairment comprises noise induced hearing loss, presbycusis, drug induced hearing loss, tinnitus, decreased hearing, etc.
The present invention provides a pharmaceutical composition for treating myocardial ischemia, comprising Salvia Miltiorrhiza medicinal material 250-700 parts by weight, Radix Notoginseng medicinal material 50-150 parts by weight, Borneolum Syntheticum 3-9 parts by weight, and ranolazine 25-100 parts by weight. According to a further aspect of the present invention, there is provided a use of a pharmaceutical composition for preparation of a medicine for prevention and/or treatment of myocardial ischemia.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
5.
APPLICATION OF A TRADITIONAL CHINESE MEDICINE COMPOSITION AND FORMULATION THEREOF IN THE PREPARATION OF MEDICAMENTS FOR PREVENTING AND/OR TREATING NOVEL CORONAVIRUS PNEUMONIA
The present invention relates to an application of a traditional Chinese medicine composition and formulation thereof in the preparation of medicaments for preventing and/or treating novel coronavirus pneumonia.
Disclosed is a pharmaceutical composition for treating myocardial ischemia, comprising 250-700 parts by weight of a Salvia miltiorrhizax radix et rhizome medicinal material, 50-150 parts by weight of a Notoginseng radix et rhizome medicinal material, 3-9 parts by weight of borneol and 25-100 parts by weight of ranolazine. The pharmaceutical composition is applied to the preparation of a drug for preventing and/or treating myocardial ischemia.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
7.
PHARMACEUTICAL COMPOSITION FOR TREATING MYOCARDIAL ISCHEMIA AND PREPARATION METHOD THEREOF
Disclosed is a pharmaceutical composition for treating myocardial ischemia, comprising 250-700 parts by weight of a Salvia miltiorrhizax radix et rhizome medicinal material, 50-150 parts by weight of a Notoginseng radix et rhizome medicinal material, 3-9 parts by weight of borneol and 25-100 parts by weight of ranolazine. The pharmaceutical composition is applied to the preparation of a drug for preventing and/or treating myocardial ischemia.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
8.
TRADITIONAL CHINESE MEDICINE COMPOSITION FOR TREATING PSORIASIS, PREPARATION METHOD THEREFOR AND USE THEREOF
A traditional Chinese medicine composition for treating psoriasis, a preparation method therefor and a use thereof. The traditional Chinese medicine composition comprises: water buffalo horn powder, Japanese honeysuckle flower, gypsum, red peony root, peony bark, charred cape jasmine fruit, baical skullcap root, raw garden burnet root, and liquorice root. The preparation method comprises: proportionally weighing out the baical skullcap root, the Japanese honeysuckle flower, the red peony root, the peony bark, the gypsum, the charred cape jasmine fruit, the garden burnet root and the liquorice root, adding water and decocting 1 to 3 times, each time using 4 to 10 times the amount (weight to volume ratio) of water and decocting for 0.5 to 3 hours; combining decoctions, filtering, vacuum concentrating the filtrate, drying same, adding the water buffalo horn powder and mixing until evenly distributed.
The present application relates to an antidepressant and anxiolytic substituted cinnamamide compound, i.e., compound M2. The present application also provides a pharmaceutical composition containing compound M2 or a solvate thereof or a pharmaceutically acceptable salt thereof, and an antidepressant, anxiolytic, or antidepressant and anxiolytic application.
C07D 317/50 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
10.
ANTIDEPRESSANT AND ANXIOLYTIC SUBSTITUTED CINNAMAMIDE COMPOUND
The present application relates to an antidepressant and anxiolytic substituted cinnamamide compound, i.e., compound M2. The present application also provides a pharmaceutical composition containing compound M2 or a solvate thereof or a pharmaceutically acceptable salt thereof, and an antidepressant, anxiolytic, or antidepressant and anxiolytic application.
C07D 317/50 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
A pharmaceutical composition is prepared from the following raw materials (in parts by weight): silybin (8.75-60), phospholipid (15-65), a Pu'er tea extract (25-200), and vitamin E (6.25-40). The composition has the effect of treating non-alcoholic fatty liver diseases.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
12.
Traditional Chinese medicine composition, and preparation and application thereof
A traditional Chinese medicine composition for treating cardiovascular disease, and a preparation thereof, particularly a micro drop pill preparation thereof, and a method for preparing the preparation; the method for preparing the micro drop pill preparation can be used to prepare drop pills, coated drop pills, and drop pill capsules with a high drug loading capacity.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
13.
Traditional Chinese medicine composition, and preparation and application thereof
A traditional Chinese medicine composition for treating cardiovascular disease, and a preparation thereof, particularly a micro drop pill preparation thereof, and a method for preparing the preparation; the method for preparing the micro drop pill preparation can be used to prepare drop pills, coated drop pills, and drop pill capsules with a high drug loading capacity.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A traditional Chinese medicine composition having mental relief and antidepressant effects and a preparation method therefor. The traditional Chinese medicine composition has two formulas: formula 1, comprising in parts by weight: 10 to 30 parts of Radix bupleuri, 10 to 30 parts of Radix paeoniae alba, 15 to 30 parts of Rhizoma atractylodis macrocephalae stir-fried with wheat bran, 10 to 30 parts of Angelica sinensis, and 15 to 24 parts of honey-fried licorice root; and formula 2, comprising in parts by weight: 10 to 30 parts of Radix bupleuri, 10 to 30 parts of Radix paeoniae alba, 15 to 30 parts of Rhizoma atractylodis macrocephalae stir-fried with wheat bran, 10 to 30 parts of Angelica sinensis, 10 to 30 parts of Poria cocos, and 15 to 24 parts of honey-fried licorice root.
APPLICATION OF A TRADITIONAL CHINESE MEDICINE COMPOSITION AND FORMULATION THEREOF IN THE PREPARATION OF MEDICAMENTS FOR PREVENTING AND/OR TREATING NOVEL CORONAVIRUS PNEUMONIA
A traditional Chinese medicine composition prepared from Radix Salviae Miltiorrhizae and Panax Notoginseng extracts and Borneolum Syntheticum, and an application of a preparation of the traditional Chinese medicine composition in preparing medicine for preventing and/or treating ?coronavirus disease 2019.
TRADITIONAL CHINESE MEDICINE COMPOSITION, AND APPLICATION OF PREPARATION OF TRADITIONAL CHINESE MEDICINE COMPOSITION IN PREPARING MEDICINE FOR PREVENTING AND/OR TREATING CORONAVIRUS DISEASE 2019
A traditional Chinese medicine composition prepared from Radix Salviae Miltiorrhizae and Panax Notoginseng extracts and Borneolum Syntheticum, and an application of a preparation of the traditional Chinese medicine composition in preparing medicine for preventing and/or treating coronavirus disease 2019.
A traditional Chinese medicine composition for treating psoriasis, a preparation method therefor and a use thereof. The traditional Chinese medicine composition comprises: water buffalo horn powder, Japanese honeysuckle flower, gypsum, red peony root, peony bark, charred cape jasmine fruit, baical skullcap root, raw garden bumet root, and liquorice root. The preparation method comprises: proportionally weighing out the baical skullcap root, the Japanese honeysuckle flower, the red peony root, the peony bark, the gypsum, the charred cape jasmine fruit, the garden bumet root and the liquorice root, adding water and decocting 1 to 3 times, each time using 4 to 10 times the amount (weight to volume ratio) of water and decocting for 0.5 to 3 hours; combining decoctions, filtering, vacuum concentrating the filtrate, drying same, adding the water buffalo horn powder and mixing until evenly distributed.
A traditional Chinese medicine composition for treating psoriasis, a preparation method therefor and a use thereof. The traditional Chinese medicine composition comprises: water buffalo horn powder, honeysuckle, gypsum, red peony root, peony root bark, Gardenia jasminoides fruit, Scutellaria baicalensis, garden burnet root, and licorice. The preparation method comprises: proportionally weighing out the Scutellaria baicalensis, the honeysuckle, the red peony root, the peony root bark, the gypsum, the Gardenia jasminoides fruit, the garden burnet root and the licorice, adding water and decocting 1 to 3 times, each time using 4 to 10 times the amount (weight to volume ratio) of water and decocting for 0.5 to 3 hours; combining decoctions, filtering, vacuum concentrating the filtrate, drying same, adding the water buffalo horn powder and mixing until evenly distributed.
Disclosed are a pharmaceutical composition and an application thereof. The pharmaceutical composition of the present invention comprises the following components in parts by weight: 2-20 parts of phenolic acids, 0.5-5 parts of flavonoids, 0.005-0.5 part of tanshinones, 5-20 parts of saponins, and 10-18 parts of volatile oils. The pharmaceutical composition has the functions of protecting against myocardial damage and treating heart failure.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
20.
PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
Disclosed are a pharmaceutical composition and an application thereof. The pharmaceutical composition of the present invention comprises the following components in parts by weight: 2-20 parts of phenolic acids, 0.5-5 parts of flavonoids, 0.005-0.5 part of tanshinones, 5-20 parts of saponins, and 10-18 parts of volatile oils. The pharmaceutical composition has the functions of protecting against myocardial damage and treating heart failure.
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
21.
PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
Disclosed are a pharmaceutical composition and an application thereof. The pharmaceutical composition of the present invention comprises the following components in parts by weight: 2-20 parts of phenolic acids, 0.5-5 parts of flavonoids, 0.005-0.5 part of tanshinones, 5-20 parts of saponins, and 10-18 parts of volatile oils. The pharmaceutical composition has the functions of protecting against myocardial damage and treating heart failure.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
22.
TRADITIONAL CHINESE MEDICINE COMPOSITION FOR PREVENTING AND/OR TREATING ISCHEMIC REPERFUSION INJURY
A traditional Chinese medicine composition for preventing and/or treating ischemic reperfusion injury and an application thereof in preparing a drug for treating and/or preventing ischemic reperfusion injury or for promoting thrombolysis. The traditional Chinese medicine composition is composed of salvianolic acid, total panax notoginseng saponins, and total astragalus saponins.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
23.
Formulation of a micro drop pill and the preparation method thereof
The present invention relates to a preparation method for a traditional Chinese medicine drop pill and a traditional Chinese medicine micro drop pill prepared by using the method, and in particular, the present invention relates to a micro drop pill preparation method with high drug-loading capacity, simple preparation process and high production rate and a micro drop pill prepared by using the method. Specially, The drop pill preparation method used comprises the following steps: (1) material melting step: heat melting a medicine and a drop pill matrix to obtain a molten medicine liquid; (2) dropping step: delivering the molten medicine liquid to a dripper, and acquiring medicine drops of the molten medicine liquid by means of vibration dropping; and, (3) condensation step: cooling the medicine drops with a cooling gas to obtain micro drop pills.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61J 3/06 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
C07D 317/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07C 235/34 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
C07D 295/192 - Radicals derived from carboxylic acids from aromatic carboxylic acids
25.
NEW APPLICATION FOR LONG-ACTING MUTANT HUMAN FIBROBLAST GROWTH FACTOR
Disclosed in the present invention is a new application for a long-acting mutant human fibroblast growth factor, the long-acting mutant human fibroblast growth factor being PEGylation Recombinant Human-mouse Chimeric Fibroblast Growth Factor 21, and the new application being the preparation of a drug for the treatment of non-alcoholic steatohepatitis.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
26.
Intelligent dripping pill machine for continuous liquid solidification
An intelligent dripping pill machine for continuous liquid solidification comprises: a feeding device (1), a material combining device (2), a homogenizing device (3), a dripping device (4) and a de-oiling device (5) sequentially connected via a transmission channel. The intelligent dripping pill machine removes, via high-speed centrifugation, a cooling liquid attached to dripping pills, and each component device is connected compactly, thereby achieving a continuous manufacturing operation, and reducing an occupied space of the devices as a whole while ensuring the yield of the dripping pills.
A61J 3/06 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
27.
Intelligent continuous manufacturing method via liquid cooling of dripping pills
An intelligent continuous manufacturing method via liquid cooling of dripping pills comprises the following steps: (1) feeding: weighing and transferring multiple materials respectively; (2) material combining: performing staged heating on the materials transferred in step (1), and mixing the same to obtain a material mixture, wherein an RSD of an effective ingredient in the material mixture ≤5%; (3) homogenizing: pressurizing the material mixture obtained in step (2), and increasing the temperature, so as to obtain a homogenized material having the RSD of the effective ingredient in the material mixture ≤5%; (4) dripping: performing vibration dripping on the homogenized material obtained in step (3) to obtain dripping pills, delivering the dripping pills into a cooling liquid to be cooled and then transferred; and (5) de-oiling: removing the cooling liquid on surfaces of the dripping pills obtained in step (4) via tilting centrifugation. The manufacturing method not only shortens the manufacturing process, but also ensures the dripping pill product to be more stable and homogeneous. In addition, high-speed centrifugation is used to reasonably de-oil the dripping pills to prevent contamination of the dripping pills and improve the circulation utilization rate of the cooling liquid.
A61J 3/06 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
Disclosed are a pharmaceutical composition for treating non-alcoholic fatty liver and a method for preparing same. The composition is prepared from the following hulk drugs by weight ratio: 8.75-60 parts of silibinin, 15-65 parts of phospholipid, 25-200 parts of Pu'er tea extract, and 5-50 parts of radix puerariae extract.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A pharmaceutical composition for treating non-alcoholic fatty liver diseases. The pharmaceutical composition is prepared from 8.75-60 parts by weight of silybin, 15-65 parts by weight of phospholipid, 25-150 parts by weight of a Pu'er tea extract, and 10.425-60 parts by weight of L-carnitine.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A pharmaceutical composition. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 8.75-60 parts of silybin, 15-65 parts of phospholipid, 25-200 parts of a Pu'er tea extract, 6.25-40 parts of vitamin E, and 8.3-60 parts of L-carnitine. The composition can be used for treating non-alcoholic fatty liver diseases.
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A pharmaceutical composition is prepared from the following raw materials (in parts by weight): silybin (8.75-60), phospholipid (15-65), a Pu'er tea extract (25-200), and vitamin E (6.25-40). The composition has the effect of treating non-alcoholic fatty liver diseases.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Disclosed is a pharmaceutical composition containing silibinin, which is prepared from the following bulk drugs by weight ratio: 8.75-60 parts of silibinin, 15-65 parts of phospholipid, and 25-200 parts of Pu'er tea extract. The drug has the function of treating non-alcoholic fatty liver.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A pharmaceutical composition for treating non-alcoholic fatty liver diseases consists of a silybin-phospholipid complex preparation and Pu'er tea/tea product according to a weight ratio of 0.5-2.5:0.3-10, wherein the silybin-phospholipid complex capsule preparation and the Pu'er teat/tea product are separately packaged.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
B65D 81/32 - Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A silybin injection contains silybin, sulfobutyl ether-β-cyclodextrin, an organic solvent for injection, a pH regulator, and may further contain a co-solvent, a lyophilization bulking agent, and water for injection.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicines for human purposes; chemico-pharmaceutical
preparations; raw material medicine; biomedicine;
pharmaceutical herbs for medical purposes; prepared Chinese
medicine; capsules for medicines; pharmaceutical
preparations; dietetic substances adapted for medical use;
bath preparations, medicated; balsamic preparations for
medical purposes; preparations for the treatment of burns;
syrups for pharmaceutical purposes; vitamin preparations;
sunburn preparations for pharmaceutical purposes; vaccines;
detergents for medical purposes; disinfectants for hygiene
purposes; digestives for pharmaceutical purposes; drugs for
medical purposes; medicine cases, portable, filled; mineral
water for medical purposes; salts for medical purposes;
purgatives; meal for pharmaceutical purposes; flour for
pharmaceutical purposes; febrifuges; medicinal tea;
nervines; anthelmintics; gelatine for medical purposes;
germicides; greases for medical purposes; chemical
preparations for the diagnosis of pregnancy; medicinal oils;
medicinal herbs; lotions for pharmaceutical purposes;
ointments for pharmaceutical purposes; pectin for
pharmaceutical purposes; herbs teas for medicinal purposes;
pharmaceutical preparations for skin care; pharmaceutical
preparations for treating dandruff; first-aid boxes, filled;
medicinal roots; tonics [medicine]; sedatives; soporifics;
sugar for medical purposes; biological preparations for
medical purposes; medical preparations for slimming
purposes; by-products of the processing of cereals for
dietetic or medical purposes; chemical preparations for
pharmaceutical purposes; medicines for dental purposes;
diagnose preparations for medical purposes; medicinal
drinks; ferments for pharmaceutical purposes; chemical
preparations for medical purposes; chemical reagents for
medical or veterinary purposes; dietary fiber; enzyme
preparations for medical purposes; amino acids for
pharmaceutical purposes; mouthwashes for medical purposes;
appetite suppressants for medical purposes; adjuvants for
medical purposes; weight-reducing aid; medicine for the
treatment of tanning skin; antioxidant medicine; acne
treatment preparation; lysine electuary; oral rehydration
salts; medicinal liquor; ginseng electuary; ginseng (term
considered too vague by the International Bureau - Rule
13.2.b of the Common Regulations); medlar (term considered
too vague by the International Bureau - Rule 13.2.b of the
Common Regulations); weight-reducing tea; dietetic foods
adapted for medical purposes; dietetic beverages adapted for
medical purposes; nutritional additives for medical
purposes; food for babies; milk powder for infants; air
purifying preparations; animal washes; veterinary
preparations; feed, containing drugs (term considered too
vague by the International Bureau - Rule 13.2.b of the
Common Regulations); biocides; vermin destroying
preparations; sanitary towels; wadding for medical purposes;
medical dressings; rubber for dental purposes; teeth filling
material; diaper for pets.
36.
APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATIONS
Disclosed is an application of substituted cinnamamide derivatives in the preparation of Anti-anxiety medications, the substituted cinnammide derivatives are compounds having the structure of formula (I) or pharmaceutically acceptable salts thereof, wherein, R1 is H, -OH, -F, -Cl, -Br, -I, -OCH 3, -OCF 3, -OCHF 2, -OCH 2F, -CF 3, -CHF 2, -CH 2F, -CH 3, -CH 3CH 2, -CF 3CH 2, -CN, -NO 2, -NH 2 or -COOR 5; R 2 is H, C 1-C 10 linear alkyl, C 3-C 10 branched alkyl, C 3-C 10 cyclic alkyl, C 1-C 10 hydroxyalkyl or a N-substituted piperazine-derived group; or R 2 is a group forming with adjacent Y a tetrahydropyrrolyl group, a piperidyl group or a cyclohexanimido group.
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
Disclosed is an application of substituted cinnamamide derivatives in the preparation of Anti-anxiety medications, the substituted cinnammide derivatives are compounds having the structure of formula (I) or pharmaceutically acceptable salts thereof, wherein, R1 is –H, -OH, -F, -Cl, -Br, -I, -OCH 3, -OCF 3, -OCHF 2, -OCH 2F, -CF 3, -CHF 2, -CH 2F, -CH 3, -CH 3CH 2, -CF 3CH 2, -CN, -NO 2, -NH 2 or -COOR 5; R 2 is H, C 1-C 10 linear alkyl, C 3-C 10 branched alkyl, C 3-C 10 cyclic alkyl, C 1-C 10 hydroxyalkyl or a N-substituted piperazine-derived group; or R 2 is a group forming with adjacent Y a tetrahydropyrrolyl group, a piperidyl group or a cyclohexanimido group.
C07D 317/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07C 235/34 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
C07D 295/192 - Radicals derived from carboxylic acids from aromatic carboxylic acids
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
A traditional Chinese medicine composition for treating cardiovascular disease, and a preparation thereof, particularly a micro drop pill preparation thereof, and a method for preparing the preparation; the method for preparing the micro drop pill preparation can be used to prepare drop pills, coated drop pills, and drop pill capsules with a high drug loading capacity.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
An intelligent dripping pill machine for continuous liquid solidification comprises: a feeding device (1), a material combining device (2), a homogenizing device (3), a dripping device (4) and a de-oiling device (5) sequentially connected via a transmission channel. The intelligent dripping pill machine removes, via high-speed centrifugation, a cooling liquid attached to dripping pills, and each component device is connected compactly, thereby achieving a continuous manufacturing operation, and reducing an occupied space of the devices as a whole while ensuring the yield of the dripping pills.
A61J 3/06 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
40.
INTELLIGENT CONTINUOUS MANUFACTURING METHOD VIA LIQUID COOLING OF DRIPPING PILLS
An intelligent continuous manufacturing method via liquid cooling of dripping pills comprises the following steps: (1) feeding: weighing and transferring multiple materials respectively; (2) material combining: performing staged heating on the materials transferred in step (1), and mixing the same to obtain a material mixture, wherein an RSD of an effective ingredient in the material mixture = 5%; (3) homogenizing: pressurizing the material mixture obtained in step (2), and increasing the temperature, so as to obtain a homogenized material having the RSD of the effective ingredient in the material mixture = 5%; (4) dripping: performing vibration dripping on the homogenized material obtained in step (3) to obtain dripping pills, delivering the dripping pills into a cooling liquid to be cooled and then transferred; and (5) de-oiling: removing the cooling liquid on surfaces of the dripping pills obtained in step (4) via tilting centrifugation. The manufacturing method not only shortens the manufacturing process, but also ensures the dripping pill product to be more stable and homogeneous. In addition, high-speed centrifugation is used to reasonably de-oil the dripping pills to prevent contamination of the dripping pills and improve the circulation utilization rate of the cooling liquid.
A61J 3/06 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
41.
INTELLIGENT DRIPPING PILL MACHINE FOR CONTINUOUS LIQUID SOLIDIFICATION
An intelligent dripping pill machine for continuous liquid solidification comprises: a feeding device (1), a material combining device (2), a homogenizing device (3), a dripping device (4) and a de-oiling device (5) sequentially connected via a transmission channel. The intelligent dripping pill machine removes, via high-speed centrifugation, a cooling liquid attached to dripping pills, and each component device is connected compactly, thereby achieving a continuous manufacturing operation, and reducing an occupied space of the devices as a whole while ensuring the yield of the dripping pills.
A61J 3/06 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
42.
INTELLIGENT CONTINUOUS MANUFACTURING METHOD VIA LIQUID COOLING OF DRIPPING PILLS
An intelligent continuous manufacturing method via liquid cooling of dripping pills comprises the following steps: (1) feeding: weighing and transferring multiple materials respectively; (2) material combining: performing staged heating on the materials transferred in step (1), and mixing the same to obtain a material mixture, wherein an RSD of an effective ingredient in the material mixture ≤ 5%; (3) homogenizing: pressurizing the material mixture obtained in step (2), and increasing the temperature, so as to obtain a homogenized material having the RSD of the effective ingredient in the material mixture ≤ 5%; (4) dripping: performing vibration dripping on the homogenized material obtained in step (3) to obtain dripping pills, delivering the dripping pills into a cooling liquid to be cooled and then transferred; and (5) de-oiling: removing the cooling liquid on surfaces of the dripping pills obtained in step (4) via tilting centrifugation. The manufacturing method not only shortens the manufacturing process, but also ensures the dripping pill product to be more stable and homogeneous. In addition, high-speed centrifugation is used to reasonably de-oil the dripping pills to prevent contamination of the dripping pills and improve the circulation utilization rate of the cooling liquid.
A61J 3/06 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
43.
PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND L-CARNITINE
A pharmaceutical composition for treating non-alcoholic fatty liver diseases. The pharmaceutical composition is prepared from 8.75-60 parts by weight of silybin, 15-65 parts by weight of phospholipid, 25-150 parts by weight of a Pu'er tea extract, and 10.425-60 parts by weight of L-carnitine.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Disclosed are a pharmaceutical composition for treating non-alcoholic fatty liver and a method for preparing same. The composition is prepared from the following bulk drugs by weight ratio: 8.75-60 parts of silibinin, 15-65 parts of phospholipin, 25-200 parts of Pu'er tea extract, and 5-50 parts of pueraria root extract.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A pharmaceutical composition for treating non-alcoholic fatty liver diseases consists of a silybin-phospholipid compound preparation and Pu'er tea/tea product according to a weight ratio of 0.5-2.5:0.3-10, wherein the silybin-phospholipid compound capsule preparation and the Pu'er tea/tea product are separately packaged.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Disclosed is a pharmaceutical composition containing silibinin, which is prepared from the following bulk drugs by weight ratio: 8.75-60 parts of silibinin, 15-65 parts of phospholipin, and 25-200 parts of Pu'er tea extract. The drug has the function of treating non-alcoholic fatty liver.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 9/66 - Sustained or differential release type containing emulsions, dispersions or solutions
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Disclosed is a pharmaceutical composition containing silibinin, which is prepared from the following bulk drugs by weight ratio: 8.75-60 parts of silibinin, 15-65 parts of phospholipin, and 25-200 parts of Pu'er tea extract. The drug has the function of treating non-alcoholic fatty liver.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 9/66 - Sustained or differential release type containing emulsions, dispersions or solutions
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
48.
PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND L-CARNITINE
A pharmaceutical composition for treating non-alcoholic fatty liver diseases. The pharmaceutical composition is prepared from 8.75-60 parts by weight of silybin, 15-65 parts by weight of phospholipid, 25-150 parts by weight of a Pu'er tea extract, and 10.425-60 parts by weight of L-carnitine.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
49.
PHARMACEUTICAL COMPOSITION CONTAINING SILIBININ AND PUERARIA ROOT EXTRACT
Disclosed are a pharmaceutical composition for treating non-alcoholic fatty liver and a method for preparing same. The composition is prepared from the following bulk drugs by weight ratio: 8.75-60 parts of silibinin, 15-65 parts of phospholipin, 25-200 parts of Pu'er tea extract, and 5-50 parts of pueraria root extract.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A pharmaceutical composition for treating non-alcoholic fatty liver diseases consists of a silybin-phospholipid compound preparation and Pu'er tea/tea product according to a weight ratio of 0.5-2.5:0.3-10, wherein the silybin-phospholipid compound capsule preparation and the Pu'er tea/tea product are separately packaged.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
51.
PHARMACEUTICAL COMPOSITION COMPRISING SILYBIN, PU'ER TEA EXTRACT, VITAMIN E AND L-CARNITINE
A pharmaceutical composition. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 8.75-60 parts of silybin, 15-65 parts of phospholipid, 25-200 parts of a Pu'er tea extract, 6.25-40 parts of vitamin E, and 8.3-60 parts of L-carnitine. The composition can be used for treating non-alcoholic fatty liver diseases.
A61K 31/221 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A pharmaceutical composition is prepared from the following raw materials (in parts by weight): silybin (8.75-60), phospholipid (15-65), a Pu'er tea extract (25-200), and vitamin E (6.25-40). The composition has the effect of treating non-alcoholic fatty liver diseases.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A pharmaceutical composition is prepared from the following raw materials (in parts by weight): silybin (8.75-60), phospholipid (15-65), a Pu'er tea extract (25-200), and vitamin E (6.25-40). The composition has the effect of treating non-alcoholic fatty liver diseases.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A pharmaceutical composition. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 8.75-60 parts of silybin, 15-65 parts of phospholipid, 25-200 parts of a Pu'er tea extract, 6.25-40 parts of vitamin E, and 8.3-60 parts of L-carnitine. The composition can be used for treating non-alcoholic fatty liver diseases.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/221 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present invention relates to the medical field, specifically a salvianolic acid T as described in structural formula (I), a chiral isomer thereof, a preparation method therefor, pharmaceutical compositions, antioxidants, and free radical scavengers thereof, and a use of the compound.
C07C 69/732 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
C07C 67/56 - SeparationPurificationStabilisationUse of additives by solid-liquid treatmentSeparationPurificationStabilisationUse of additives by chemisorption
A silybin injection contains silybin, sulfobutyl ether-β-cyclodextrin, an organic solvent for injection, and may further contain a co-solvent, a lyophilization proppant, a pH regulator, water for injection and the like.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A traditional Chinese medicine composition and preparation thereof for treating cardiovascular diseases is provided. The traditional Chinese medicine composition consists of: by weight percentage, phenolic acid derivatives 30%˜80%, tanshinones 2%˜10% and saponins 15%˜60%.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof
The present invention relates to an andrographolide enteric targeting micropellet and a method for preparation thereof; furthermore, the present invention also relates to uses of andrographolide and andrographolide enteric targeting micropellets in preparation of a pharmaceutical for treatment of inflammatory bowel disease.
B01J 2/00 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic
An air-cooling micro drop pill capsule production line comprises a drop pill system, an air-cooling circulation system and a control system. The drop pill system comprises a molten material tank and a dripper. A vibration apparatus is arranged between the molten material tank and the dripper, and drives the dripper to vibrate up and down. A vibration shear force cuts liquor flowing out from the dripper into drops, and drop pills are formed after the drops fall into the air-cooling circulation system and are cooled. An online monitoring apparatus is arranged on the dripper, and comprises a pulse signal emission mechanism with an emission frequency which is the same as a vibration frequency of the vibration apparatus. The control system controls and regulates a dropping parameter according to a monitoring result of the online monitoring apparatus. The present invention combines vibration dropping, online monitoring and controlling, air cooling, and fluidized drying and coating together, which satisfies the requirement of high-speed dropping, micro pill preparation and improving a drug-loading capacity. Thus, the drug-loading capacity of drop pills can be multiply improved, the usage of auxiliary materials and the dosage can be greatly reduced, organic solvent residual can be completely avoided, and requirements of different processes including slow-release coating, film coating and sugar coating can be satisfied.
A61J 3/00 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
B01J 2/18 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic using a vibrating apparatus
B01J 2/04 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a gaseous medium
B01J 2/02 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
A61J 3/06 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
62.
Traditional chinese medicine composition, and preparation and application thereof
A traditional Chinese medicine composition for treating cardiovascular disease, and a preparation thereof, particularly a micro drop pill preparation thereof, and a method for preparing the preparation; the method for preparing the micro drop pill preparation can be used to prepare drop pills, coated drop pills, and drop pill capsules with a high drug loading capacity.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
63.
Pharmaceutical composition for treating headache, and preparation method thereof
asarum, and a proper amount of adjuvant materials. A preparation method of the pharmaceutical composition, and uses thereof in the preparation of drugs for treating various headaches, traumatic cranial nerve syndrome, dizziness and vertigo, vexation and irritability, insomnia and dreaminess.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
The present invention relates to trifluoromethyl-containing amide alkaloid, a manufacturing method thereof, pharmaceutical combinations containing same, and pharmaceutical use thereof. The trifluoromethyl-containing amide alkaloid of the present invention has a structure of Formula (I). The present invention further comprises pharmaceutical application of derivatives of the alkaloid in treatment and prevention of mental disorder of melancholic depression. In Formula (I), where n is 0, 1, 2 or 3, and when n is 1, 2 or 3, the unit of Formula (II) at least contains one carbon-carbon single bond or one carbon-carbon double bond; X is N; R1 and R1' are the same or different, and are respectively H, C1-C10 linear hydrocarbon, C3-C10 branched hydrocarbon, C3-C10 cyclic hydrocarbon, C1-C10 hydroxyalkyl or N-substituted piperazine derivative; or, R1 and R1' and adjacent X form pyrrolidine, piperidine or hexamethyleneimine; R2 is H, OH, OR4, F, Cl, Br, I, C1-C10 linear hydrocarbon, C3-C10 branched hydrocarbon, CF3, CHF2, CH2F, NO2, NH2, OCF3, OCHF2, OCH2F, -O-C(=O)-R4 or -C(=O)O-R4; R3 is H, OH, OR4, F, Cl, Br, I, C1-C10 linear hydrocarbon, C3-C10 branched hydrocarbon, CF3, CHF2, CH2F, NO2, NH2, OCF3, OCHF2, OCH2F, -O-C(=O)-R4 or -C(=O)O-R4; and R4 is C1-C10 linear hydrocarbon, C3-C10 branched hydrocarbon, C3-C10 cyclic hydrocarbon, C4-C12 cyclic hydrocarbon/alkyl, and C1-C10 hydroxyalkyl.
C07C 233/11 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
Use of a traditional Chinese medicine composition in preparation of medicine for treating Alzheimer's disease (senile dementia). The traditional Chinese medicine composition is prepared from Radix Angelicae Sinensis 6.75%, Rhizoma Chuanxiong 6.75%, Radix Paeoniae Alba 5.4%, Ramulus Uncariae Cum Uncis 13.5%, Caulis Spatholobi 13.5%, Radix Rehmanniae Preparata 5.4%, Semen Cassiae 13.5%, Spica Prunellae 13.5%, Herba Asari 1.34%, Rhizoma Corydalis 6.75% and Concha Margaritifera Usta 13.5%.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A traditional Chinese medicinal composition and preparation thereof having effect of treating cardiovascular. The traditional Chinese medicinal composition consists of: by weight percentage, phenolic acids 30%-80%, tanshinones ingredient 2%-10% and saponins ingredient 15%-60%.
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A traditional Chinese medicinal composition and preparation thereof having effect of treating cardiovascular. The traditional Chinese medicinal composition consists of: by weight percentage, phenolic acids 30%-80%, tanshinones ingredient 2%-10% and saponins ingredient 15%-60%.
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
68.
NEW SALVIANOLIC ACID COMPOUND T, PREPARATION METHOD THEREFOR, AND USE THEREOF
The present abstract relates to the medical field, specifically a salvianolic acid T as described in structural formula (I), a chiral isomer thereof, a preparation method therefor, pharmaceutical compositions, antioxidants, and free radical scavengers thereof, and a use of the compound.
C07C 67/31 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
C07C 67/48 - SeparationPurificationStabilisationUse of additives
C07C 69/732 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
69.
NEW SALVIANOLIC ACID COMPOUND T, PREPARATION METHOD THEREFOR, AND USE THEREOF
The present abstract relates to the medical field, specifically a salvianolic acid T as described in structural formula (I), a chiral isomer thereof, a preparation method therefor, pharmaceutical compositions, antioxidants, and free radical scavengers thereof, and a use of the compound.
C07C 69/732 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
C07C 67/31 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
C07C 67/48 - SeparationPurificationStabilisationUse of additives
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61P 9/00 - Drugs for disorders of the cardiovascular system
APPLICATION OF ANDROGRAPHOLIDE IN THE PREPARATION OF A PHARMACEUTICAL FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE, ANDROGRAPHOLIDE ENTERIC TARGETING MICROPELLET, AND METHOD FOR PREPARATION THEREOF
The present invention relates to an andrographolide enteric targeting micropellet and method for preparation thereof; furthermore, the present invention also relates to uses of andrographolide and andrographolide enteric targeting micropellets in the preparation of a pharmaceutical for treatment of inflammatory bowel disease.
A traditional Chinese medicine composition and a preparation thereof, and in particular, a micro drop pill. The traditional Chinese medicine composition comprises 50.0% to 99.9% of salvia miltiorrhiza and Panax notoginseng extract and 0.1% to 50.0% of borneol (by weight percentage). The salvia miltiorrhiza and Panax notoginseng extract comprises the following components (by weight percentage): salvianic acid A: salvianolic acid T: protocatechuic aldehyde: salvianolic acid D: rosmarinic acid: salvianolic acid B: salvianolic acid A: Notoginsenoside R1: ginsenoside Rg1: ginsenoside Re: ginsenoside Rb1: ginsenoside Rd: dihydrotanshinoneI: tanshinone I: cryptotanshinone: tanshinone II? = (2-5): (0.5-1.9): (1.1-3): (0.2-1.2): (0.2-1): (0.5-2): (0.5-2): (0.2-1): (1.5-4): (0.1-0.5): (1-3.9): (0.1-1): (0.01-0.05): (0.05-0.1): (0.02-0.1): (0.1-0.5). A preparation method for the micro drop pill comprises vibration dropping, air cooling, and the like. The method can be used to manufacture drop pills, coated drop pills, and drop pill capsules with a high drug loading capacity. The composition has an effect of treating acute myocardial ischemia and acute myocardial infarction.
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
72.
FORMULATION OF A MICRO DROP PILL AND THE PREPARATION METHOD THEREOF
A preparation method for a traditional Chinese medicine micro drop pill and a traditional Chinese medicine micro drop pill prepared by using the method, and in particular, a micro drop pill preparation method that achieves a high drug loading capacity and has a simple preparation process and a high production rate, and a micro drop pill prepared by using the method. Specifically, the drop pill preparation method used comprises the following steps: (1) a material melting step: heating and melting medicine and a drop pill matrix to obtain a molten liquor; (2) a dropping step: delivering the molten liquor to a dripper, and acquiring drops of the molten liquor by means of vibration dropping; and (3) a condensation step: cooling the medicine drops with cooling air, to obtain micro drop pills.
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
73.
TRADITIONAL CHINESE MEDICINE COMPOSITION, AND PREPARATION AND APPLICATION THEREOF
A traditional Chinese medicine composition for treating cardiovascular disease, and a preparation thereof, particularly a micro drop pill preparation thereof, and a method for preparing the preparation; the method for preparing the micro drop pill preparation can be used to prepare drop pills, coated drop pills, and drop pill capsules with a high drug loading capacity.
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
An air-cooling drop pill production line comprises a drop pill system, an air-cooling circulation system, and a control system. The drop pill system comprises a molten material tank and a dripper; a vibration apparatus is arranged between the molten material tank and the dripper; the vibration apparatus drives the dripper to vibrate up and down. A vibration shear force cuts liquor flowing out from the dripper into drops, and after the drops fall into the air-cooling circulation system and are cooled, drop pills are formed. An online monitoring apparatus is arranged on the dripper, and the apparatus comprises a pulse signal emission mechanism; an emission frequency of the pulse signal emission mechanism is the same as a vibration frequency of the vibration apparatus. The control system controls a dropping parameter according to a monitoring result of the online monitoring apparatus. The vibration dropping, online monitoring and control, air cooling, and fluidized drying and coating are combined together, which satisfies the requirement of high-speed dropping and drop pill preparation and the requirement of improving a drug loading capacity, improves the drug loading capacity of drop pills exponentially, significantly reduces the usage of auxiliary materials and the dosage, completely avoids any residual organic solvent, and satisfies requirements of different processes including slow-release coating, film coating, and sugar coating.
A61J 3/06 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
75.
PREPARATION METHOD FOR TRADITIONAL CHINESE MEDICINE MICRO DROP PILL AND TRADITIONAL CHINESE MEDICINE MICRO DROP PILL PREPARED BY USING THE METHOD
A preparation method for a traditional Chinese medicine micro drop pill and a traditional Chinese medicine micro drop pill prepared by using the method, and in particular, a micro drop pill preparation method that achieves a high drug loading capacity and has a simple preparation process and a high production rate, and a micro drop pill prepared by using the method. Specifically, the drop pill preparation method used comprises the following steps: (1) a material melting step: heating and melting medicine and a drop pill matrix to obtain a molten liquor; (2) a dropping step: delivering the molten liquor to a dripper, and acquiring drops of the molten liquor by means of vibration dropping; and (3) a condensation step: cooling the medicine drops with cooling air, to obtain micro drop pills.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 9/00 - Drugs for disorders of the cardiovascular system
A traditional Chinese medicine composition and a preparation thereof, and in particular, a micro drop pill. The traditional Chinese medicine composition comprises 50.0% to 99.9% of salvia miltiorrhiza and Panax notoginseng extract and 0.1% to 50.0% of borneol (by weight percentage). The salvia miltiorrhiza and Panax notoginseng extract comprises the following components (by weight percentage): salvianic acid A: salvianolic acid T: protocatechuic aldehyde: salvianolic acid D: rosmarinic acid: salvianolic acid B: salvianolic acid A: Notoginsenoside R1: ginsenoside Rg1: ginsenoside Re: ginsenoside Rb1: ginsenoside Rd: dihydrotanshinoneI: tanshinone I: cryptotanshinone: tanshinone IIΑ = (2-5): (0.5-1.9): (1.1-3): (0.2-1.2): (0.2-1): (0.5-2): (0.5-2): (0.2-1): (1.5-4): (0.1-0.5): (1-3.9): (0.1-1): (0.01-0.05): (0.05-0.1): (0.02-0.1): (0.1-0.5). A preparation method for the micro drop pill comprises vibration dropping, air cooling, and the like. The method can be used to manufacture drop pills, coated drop pills, and drop pill capsules with a high drug loading capacity. The composition has an effect of treating acute myocardial ischemia and acute myocardial infarction.
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
77.
TRADITIONAL CHINESE MEDICINE COMPOSITION, AND PREPARATION AND APPLICATION THEREOF
A traditional Chinese medicine composition for treating cardiovascular disease, and a preparation thereof, particularly a micro drop pill preparation thereof, and a method for preparing the preparation; the method for preparing the micro drop pill preparation can be used to prepare drop pills, coated drop pills, and drop pill capsules with a high drug loading capacity.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
Use of Chinese medicine preparation in preparing a drug for preventing and/or treating Crohn's disease. The Chinese medicine preparation is made of 1% to 10% of dragon's blood by weight, 15% to 40% of red peony root by weight, 1% to 20% of natural indigo by weight, 1% to 10% of red halloysite by weight, 15% to 40% of catechu by weight, 1% to 10% of burnt alum by weight, 5% to 30% of Common Bletilla Tuber by weight, and 1% to 10% of calamina by weight.
A salvia miltiorrhiza extract, a micropellet formulation thereof, methods of preparing same, and uses thereof are disclosed. The salvia miltiorrhiza extract contains the following component weight ratio: salvia miltiorrhiza elements : rosmarinic acid : lithospermic acid : salvianolic acid B : cryptotanshinone : tanshinone II A : stachyose = (0.5-16) : (0.5-15) : (0.5-15) : (5-140) : (0.5-25) :(1-50) : (150-600). The salvia miltiorrhiza extract of the present invention also contains a liposoluble active ingredient and a water-soluble active ingredient of salvia miltiorrhiza. The invention has excellent stability, contains low amounts of solvent residue, improves microcirculation, and reduces blood lipid levels.
A pharmaceutical composition for treating headache, prepared from eleven Chinese herbal medicines: Chinese angelica root, ligusticum chuanxiong, radix paeoniae lactiflorae, prepared rhizome of rehmannia, uncaria tomentosa, leatherleaf milletia, prunella vulgaris, sicklesenna seed, pearl shell, corydalis tuber, and asarum, and a proper amount of adjuvant materials. A preparation method of the pharmaceutical composition, and uses thereof in the preparation of drugs for treating various headaches, traumatic cranial nerve syndrome, dizziness and vertigo, vexation and irritability, insomnia and dreaminess.
A pharmaceutical composition for treating headache, prepared from eleven Chinese herbal medicines: Chinese angelica root, ligusticum chuanxiong, radix paeoniae lactiflorae, prepared rhizome of rehmannia, uncaria tomentosa, leatherleaf milletia, prunella vulgaris, sicklesenna seed, pearl shell, corydalis tuber, and asarum, and a proper amount of adjuvant materials. A preparation method of the pharmaceutical composition, and uses thereof in the preparation of drugs for treating various headaches, traumatic cranial nerve syndrome, dizziness and vertigo, vexation and irritability, insomnia and dreaminess.
The present invention relates to substituted cinnamamide derivatives, the method for preparing thereof and the use thereof. Each of said derivatives has a structure of formula (I). The method for preparing the substituted cinnamamides and their derivatives of the present invention is also disclosed. Substituted piperonal derivatives are selected as starting materials to prepare the substituted cinnamamide derivatives of the present invention by Wittig reaction and acid-amine condensation reaction. Further, a use of the present compounds in preventing and treating depressive-type mental diseases is disclosed.
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 317/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 317/62 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
C07D 317/50 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
C07D 317/52 - Radicals substituted by halogen atoms or nitro radicals
83.
Use of a Chinese medicine composition in preparing medicaments for treating secondary prevention of myocardial infarction
The present invention relates to a use of Chinese medicine composition in preparation of medicine for secondary prevention of myocardial infarction. Said Chinese medicine composition is prepared from a formula comprising the crude drugs by the following weight percentages: Radix Astragali 22.2%˜66.8%, Radix Salviae Miltiorrhizae 11.6%˜33.4%, Radix Notoginseng 2.5%˜13.5%, and Lignum Dalbergiae Odoriferae 14.5%˜44.3%.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of stable angina type coronary heart disease and the reduction of serious vascular events.
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
85.
Chenopodium ambrosioides L., the compositions comprising said extracts, the preparing process and application thereof
Helicobacter Pylori-induced diseases of digestive system, such as gastritis, gastric ulcer, etc., with easy availability of raw materials, simple preparations, prominent effects, and less side-effect.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61K 9/64 - Organic coatings containing proteins or derivatives thereof
86.
USES OF DANSHEN OR DANSHEN PREPARATION IN PREPARATION OF DRUGS FOR TREATING DISEASES RELATED TO HEPATIC FIBROSIS
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present invention relates to a substituted cinnamamide derivative, a preparation method and the use thereof. The substituted cinnamamide derivative of the present invention has a structure as represented by formula (I). Also disclosed are a method for preparing the substituted cinnamamide of the present invention and the derivatives thereof by using the substituted piperonal derivatives as raw materials via a Wittig reaction and an acid-amine condensation reaction, and the use thereof as a medicament for the treatment and prevention of depressive psychoses.
C07D 317/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 317/62 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
The present invention relates to a substituted cinnamamide derivative, a preparation method and the use thereof. The substituted cinnamamide derivative of the present invention has a structure as represented by formula (I). Also disclosed are a method for preparing the substituted cinnamamide of the present invention and the derivatives thereof by using the substituted piperonal derivatives as raw materials via a Wittig reaction and an acid-amine condensation reaction, and the use thereof as a medicament for the treatment and prevention of depressive psychoses.
C07D 317/62 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
C07D 317/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
A capsule of compound danshen dripping pills are disclosed. The color of the capsule's shell is orange, yellow, green or blue and all of these colors are in the wavelength range of 446-620 nm.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
Use of Danshensu, Notoginsenoside R1 or their combination in preparation of medicaments for preventing and treating diseases caused by microcirculation disorder
The present invention relates to a new use of traditional Chinese drug products of Danshensu (DLA), Notoginsenoside R1 (R1) and their combination, in particular to the therapeutic and preventive effects of DLA, R1 and their combination on the diseases caused by microcirculation disorder.
C07C 59/52 - Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
91.
Traditional Chinese drug comprising Danshen extracts and Sanqi extracts and use thereof
The present invention discloses a traditional Chinese drug consisting of Danshen extract and Sanqi extract, the pharmaceutical composition comprising the above traditional Chinese drug as an active component and the use thereof. The traditional Chinese drug consists of Danshen extract and Sanqi extract in a weight ratio of (2˜6):(0.5˜2). The invention further discloses the effect of the above traditional Chinese drug and the pharmaceutical composition comprising the above traditional Chinese drug as an active component for treating cardiac microcirculation disorder and myocardial damage induced by ischemia/reperfusion.
A61K 36/25 - Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A pharmaceutical composition for treating macular degeneration is consisting of Astragalus membranaceus (Fisch.) Bunge, Angelica sinensis, Poria cocos (Schw.) Wolf, Fritillaria thunbergii Miq., Panax pseudo-ginseng var. notoginseng, charred Radix et Rhizoma Rhei, Pollen Typhae, and Curcuma aromatica Salisb. The pharmaceutical composition is added with conventional adjuvants, and prepared, following a conventional process, into various pharmaceutically acceptable dosage forms including decoction, tablet, capsule, bolus, oral liquid preparation, and injection. The pharmaceutical composition can enhance and stabilize the vision of an AMD patient, promote absorption of hemorrhage, reduce macular area CNV fluorescein leakage, have a desired inhibition effect on CNV of BN rats induced by laser, and have a certain effect in inhibiting or stabilizing the growth of choroidal neovascularization membrane.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
93.
USE OF COMPOUND SALVIA MILTIORRHIZA PREPARATION IN PREPARING MEDICAMENT FOR RESISTING PULMONARY HYPERTENSION
Disclosed are uses of a preparation made from salvia miltiorrhiza, panax pseudo-ginseng and borneol in preparing medicaments for resisting pulmonary hypertension, pulmonary heart disease, emphysema or congestive heart failure.
Provided is the use of a Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease, and particularly the use of the Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of stable angina type coronary heart disease and the reduction of serious vascular events.
A61K 36/53 - Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
95.
USE OF SALVIA MILTIORRHIZA COMPOSITION IN PREPARING DRUGS FOR SECONDARY PREVENTION OF CORONARY HEART DISEASE
Provided is the use of a Salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease, and particularly the use of the Salvia miltiorrhiza composition in preparing drugs for secondary prevention of stable angina type coronary heart disease and the reduction of serious vascular events.
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
96.
PHARMACEUTICAL COMPOSITION OF SILYBIN AND PREPARATION METHOD THEREOF
A pharmaceutical composition of silybin and a preparation method thereof. The pharmaceutical composition comprises a silybin infusion solution and a liquid infusion solvent; both are respectively held in a container and packaged together. The silybin infusion solution comprises an active ingredient, a phospholipid, and infusion solvent A. The liquid infusion solvent comprises a bile salt and infusion solvent B.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
97.
USE OF A CHINESE MEDICINE COMPOSITION IN PREPARING MEDICAMENTS FOR TREATING SECONDARY PREVENTION OF MYOCARDIAL INFARCTION
A use of a chinese medicine composition in preparing medicaments for treating secondary prevention of myocardial infarction. The composition is prepared with the following crude drugs by weight percent: Radix Astragali 22.2%~66.8%, Radix Salviae Miltiorrhizae 11.6%~33.4%, Radix Notoginseng 2.5%~13.5%, Lignum Dalbergiae Odoriferae 14.5%~44.3%.
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
98.
USE OF A CHINESE MEDICINE COMPOSITION IN PREPARING MEDICAMENTS FOR TREATING SECONDARY PREVENTION OF MYOCARDIAL INFARCTION
A use of a chinese medicine composition in preparing medicaments for treating secondary prevention of myocardial infarction. The composition is prepared with the following crude drugs by weight percent: Radix Astragali 22.2%~66.8%, Radix Salviae Miltiorrhizae 11.6%~33.4%, Radix Notoginseng 2.5%~13.5%, Lignum Dalbergiae Odoriferae 14.5%~44.3%.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 9/00 - Drugs for disorders of the cardiovascular system
99.
USE OF 5'-METHOXY-3',4'-METHYLENEDIOXYCINNAMIC ACID ISOBUTYLAMIDE ON PREPARING MEDICAMENTS FOR ANTI-DEPRESSION
The use of 5'-methoxy-3',4'-methylenedioxycinnamic acid isobutylamide or pharmaceutical compositions containing the compound on preparing medicaments for preventing or treating depression is provided by the present invention. The extraction and purification process of the compound from piper plant is also provided by the present invention.
A capsule of compound danshen dripping pills are disclosed. The color of the capsule's shell is orange, yellow, green or blue and all of these colors are in the wavelength range of 446-620 nm.
A61K 36/53 - Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
